Moderna and Merck Report Positive Phase 3 Results for Personalized Melanoma Vaccine
Moderna and Merck announced positive interim results from a large Phase 3 trial of their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Keytruda, in high-risk melanoma patients. The treatment significantly improved recurrence-free and distant metastasis-free survival compared to Keytruda alone. The trial involved 1,137 patients whose tumors were surgically removed. Full data and regulatory submissions are forthcoming. The breakthrough marks the first successful late-stage mRNA cancer vaccine trial and has driven substantial stock gains for Moderna.
First-hand measurement across 9 sources
We measured how 9 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (76/100). Lens Score 40/100.
Outlets measured: businessstandard, indiatoday, moneycontrol, indianexpress, mint, hindustantimes, economictimes, moneycontrol, and 1 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 19 Aug, 01:04 pm. Other outlets followed.